FLT-PET At 6 Weeks Predicts Response Assessed by CT at 12 Weeks in Melanoma Patients Treated With Pembrolizumab.
暂无分享,去创建一个
L. Schwartz | G. Schwartz | R. Carvajal | L. Dercle | M. Trager | Y. Saenger | Emanuelle M. Rizk | L. Geskin | Luke W Barker | Grace Finkel | R. Yeh
[1] L. Schwartz,et al. Prognostic and theranostic 18F-FDG PET biomarkers for anti-PD1 immunotherapy in metastatic melanoma: association with outcome and transcriptomics , 2019, European Journal of Nuclear Medicine and Molecular Imaging.
[2] R. Houot,et al. Kinetics and nadir of responses to immune checkpoint blockade by anti-PD1 in patients with classical Hodgkin lymphoma. , 2018, European journal of cancer.
[3] J. Mountz,et al. Targeted Therapy and Immunotherapy Response Assessment with F-18 Fluorothymidine Positron-Emission Tomography/Magnetic Resonance Imaging in Melanoma Brain Metastasis: A Pilot Study , 2018, Front. Oncol..
[4] Lawrence H. Schwartz,et al. (18)F-FDG PET and CT-scan Detect New Imaging Patterns of Response and Progression in Patients with Hodgkin Lymphoma Treated by Anti-PD1 Immune Checkpoint Inhibitor , 2018 .
[5] T. Chan,et al. Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab , 2017, Cell.
[6] R. Boellaard,et al. Vemurafenib plus cobimetinib in unresectable stage IIIc or stage IV melanoma: response monitoring and resistance prediction with positron emission tomography and tumor characteristics (REPOSIT): study protocol of a phase II, open-label, multicenter study , 2017, BMC Cancer.
[7] R. Wahl,et al. A comparison of FLT to FDG PET/CT in the early assessment of chemotherapy response in stages IB–IIIA resectable NSCLC , 2017, EJNMMI Research.
[8] Shi Qi,et al. 18F-FLT and 18F-FDG PET/CT in Predicting Response to Chemoradiotherapy in Nasopharyngeal Carcinoma: Preliminary Results , 2017, Scientific Reports.
[9] Charles Ferté,et al. Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1 , 2016, Clinical Cancer Research.
[10] M. Burotto,et al. Pseudoprogression and Immune-Related Response in Solid Tumors. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] April M. Kloxin,et al. Metastatic melanoma - a review of current and future treatment options. , 2015, Acta dermato-venereologica.
[12] A. D. Van den Abbeele,et al. Cancer immunotherapy: imaging assessment of novel treatment response patterns and immune-related adverse events. , 2015, Radiographics : a review publication of the Radiological Society of North America, Inc.
[13] Bal Sanghera,et al. FLT PET-CT in evaluation of treatment response , 2014, Indian journal of nuclear medicine : IJNM : the official journal of the Society of Nuclear Medicine, India.
[14] Markus Schwaiger,et al. FLT-PET is superior to FDG-PET for very early response prediction in NPM-ALK-positive lymphoma treated with targeted therapy. , 2012, Cancer research.
[15] W. Oyen,et al. Early identification of antigen-specific immune responses in vivo by [18F]-labeled 3′-fluoro-3′-deoxy-thymidine ([18F]FLT) PET imaging , 2011, Proceedings of the National Academy of Sciences.
[16] Y. Kiniwa. [Immunotherapy for melanoma]. , 2010, Gan to kagaku ryoho. Cancer & chemotherapy.
[17] A. Ribas,et al. Imaging of CTLA4 Blockade–Induced Cell Replication with 18F-FLT PET in Patients with Advanced Melanoma Treated with Tremelimumab , 2010, Journal of Nuclear Medicine.
[18] R. Wahl,et al. From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors , 2009, Journal of Nuclear Medicine.
[19] A. Hoffbrand,et al. Alternative metabolic fates of thymine nucleotides in human cells. , 1981, The Biochemical journal.
[20] R. Rocklin. Modulation of cellular-immune responses in vivo and in vitro by histamine receptor-bearing lymphocytes. , 1976, The Journal of clinical investigation.
[21] A. Shinomiya,et al. Evaluation of 3′-deoxy-3′-[18F]-fluorothymidine (18F-FLT) kinetics correlated with thymidine kinase-1 expression and cell proliferation in newly diagnosed gliomas , 2012, European Journal of Nuclear Medicine and Molecular Imaging.
[22] J. Wolchok,et al. The heterogeneity of the kinetics of response to ipilimumab in metastatic melanoma: patient cases. , 2008, Cancer immunity.